Soleno Therapeutics Inc (SLNO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Soleno Therapeutics Inc stock (SLNO) is currently trading at $31.34. Soleno Therapeutics Inc PE ratio is 85.18. Soleno Therapeutics Inc PS ratio (Price-to-Sales) is 9.37. Analyst consensus price target for SLNO is $105.15. WallStSmart rates SLNO as Sell.
- SLNO PE ratio analysis and historical PE chart
- SLNO PS ratio (Price-to-Sales) history and trend
- SLNO intrinsic value — DCF, Graham Number, EPV models
- SLNO stock price prediction 2025 2026 2027 2028 2029 2030
- SLNO fair value vs current price
- SLNO insider transactions and insider buying
- Is SLNO undervalued or overvalued?
- Soleno Therapeutics Inc financial analysis — revenue, earnings, cash flow
- SLNO Piotroski F-Score and Altman Z-Score
- SLNO analyst price target and Smart Rating
Soleno Therapeutics Inc
📊 No data available
Try selecting a different time range
SLNO Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Soleno Therapeutics Inc (SLNO)
SLNO trades 1411% above its Graham fair value of $2.65, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Soleno Therapeutics Inc (SLNO) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, institutional own.. Concerns around return on equity and price/sales. Mixed signals suggest waiting for clearer direction before acting.
Soleno Therapeutics Inc (SLNO) Key Strengths (2)
Keeps $44 of every $100 in revenue after operating costs
129.08% of shares held by major funds and institutions
Supporting Valuation Data
Soleno Therapeutics Inc (SLNO) Areas to Watch (5)
Very expensive at 9.4x annual revenue
Low profitability relative to shareholder equity
Premium pricing at 3.8x book value
Small-cap company with higher risk but more growth potential
Decent profitability, keeps $11 per $100 revenue
Supporting Valuation Data
Soleno Therapeutics Inc (SLNO) Detailed Analysis Report
Overall Assessment
This company scores 38/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 4.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, Institutional Own.. Profitability is solid with Operating Margin at 44.10%.
The Bear Case
The primary concerns are Price/Sales, Return on Equity, Price/Book. Some valuation metrics including Price/Sales (9.37), Price/Book (3.81) suggest expensive pricing. Profitability pressure is visible in Return on Equity at 6.01%, Profit Margin at 11.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Sales improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 6.01% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Price/Sales and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SLNO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SLNO's Price-to-Sales ratio of 9.37x trades at a deep discount to its historical average of 458.86x (3th percentile). The current valuation is 100% below its historical high of 3201.23x set in Jul 2025, and 56% above its historical low of 6x in Jun 2022. Over the past 12 months, the PS ratio has compressed from ~2665.2x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Soleno Therapeutics Inc (SLNO) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Soleno Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 190M with 0% growth year-over-year. Profit margins of 11.0% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 601.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 49M in free cash flow and 49M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Soleno Therapeutics Inc push profit margins above 15% as the business scales?
Valuation compression risk at a P/E of 85.2x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Soleno Therapeutics Inc.
Bottom Line
Soleno Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(18 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:28:24 AM
About Soleno Therapeutics Inc(SLNO)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of rare diseases. The company is headquartered in Redwood City, California.